MBrace Therapeutics focuses on the development of antibody-drug conjugates (ADCs) as a targeted cancer therapy. Their lead product, MBRC-101, is designed to selectively target cancer cells by utilizing a human antibody linked to a cytotoxic agent. This approach allows the drug to act as a "guided missile," specifically binding to cancer cell targets, which facilitates the internalization of the drug and ultimately leads to the destruction of the cancer cells. MBrace emphasizes the importance of identifying novel targets for ADCs, particularly for cancers that are resistant to existing treatments, thereby expanding therapeutic options for patients with unmet medical needs.

To enhance their ADC development, MBrace employs proprietary technologies, including their in vivo SPARTA technology, which improves the selection of antibody-target pairs by screening in a living organism rather than relying solely on traditional in vitro methods. This technology ensures that selected antibodies can effectively localize to tumors, bind to native tumor proteins, and internalize into cancer cells, thereby increasing the efficacy of the ADCs while minimizing off-target effects. Additionally, MBrace has developed innovative methods for producing antibodies against intracellular targets, which have historically posed challenges in manufacturing. This novel approach allows for the viable development of antibodies against previously inaccessible targets, further advancing their pipeline of ADC therapeutics.

United States

MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.

MBrace Therapeutics

Company Details